HomeGreater Than Icon
Biofil Chemicals & Pharmaceuticals LtdGreater Than Icon
Biofil Chemicals & Pharmaceuticals Ltd Financials
Company Logo

Biofil Chemicals & Pharmaceuticals Ltd Financial Statement

Biofil Chemicals & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue8.47
Operating Expense8.14
Net Profit0.17
Net Profit Margin2.01
Earning Per Share0.10
EBIDTA0.34
Effective Tax Rate17.65

Biofil Chemicals & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual40.04
Operating Expenses Annual39.22
Operating Profit Annual1.31
Interest Annual0.04
Depreciation0.40
Net Profit Annual0.71
Tax Annual0.16

Biofil Chemicals & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.04
Cash Flow from Operations2.39
Cash Flow from Investing-0.02
Cash Flow from Financing-0.12
Cash Flow at the End2.28

Biofil Chemicals & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)3.25
PBIT Margin (%)2.25
PBT Margin (%)-54.57
Net PROFIT Margin (%)1.77
Return On Networth / Equity (%)1.42
Return On Networth /Employed (%)1.81
Return On Assets (%)3.90
Total Debt / Equity (X)0.03
Asset Turnover Ratio (%)2.20

Biofil Chemicals & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual8.62
Total Current Assets Annual38.41
Non Current Assets Annual8.68
Total Shareholders Funds Annual18.20
Total Assets Annual47.08

Biofil Chemicals & Pharmaceuticals Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 98.21 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Biofil Chemicals & Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.02.
In FY 2023 , Biofil Chemicals & Pharmaceuticals Ltd recorded a total revenue of approximately 40.04 Cr marking a significant milestone in the company's financial performance.
Biofil Chemicals & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.3% annually, respectively..
Biofil Chemicals & Pharmaceuticals Ltd's current PE ratio is 138.32.
Biofil Chemicals & Pharmaceuticals Ltd's ROCE averaged 5.2% from the FY ending March 2022 to 2024, with a median of 4.9%. It peaked at 6.1% in March 2022, reflecting strong capital efficiency over the period..
Biofil Chemicals & Pharmaceuticals Ltd's latest EBIT is Rs. 0.91 Cr, surpassing the average EBIT of Rs. 0.93 Cr over the 5 years..